|1.||Jahn, Holger: 2 articles (01/2006 - 12/2003)|
|2.||Raedler, Thomas J: 2 articles (01/2006 - 12/2003)|
|3.||Goedeken, Birgit: 2 articles (01/2006 - 12/2003)|
|4.||Wiedemann, Klaus: 2 articles (01/2006 - 12/2003)|
|5.||Kellner, Michael: 2 articles (01/2006 - 12/2003)|
|6.||Gescher, Dorothee M: 2 articles (01/2006 - 12/2003)|
|7.||Allen, Carrie: 1 article (07/2015)|
|8.||Zarowitz, Barbara J: 1 article (07/2015)|
|9.||O'Shea, Terrence: 1 article (07/2015)|
|10.||Strauss, Marcie E: 1 article (07/2015)|
|1.||Breast Neoplasms (Breast Cancer)
11/01/2003 - "An economic model was developed based on data from phase III megestrol-controlled clinical trials of antiaromatase agents (AA) and estimates of resource utilization from both Statistic Canada's Population Health Model for breast cancer and expert opinion. "
04/02/1984 - " Megestrol, a gestagen, was found to cause breast tumors in beagles and was withdrawn from the market. "
10/01/1999 - "It has been shown to be effective third-line therapy after tamoxifen and megestrol in postmenopausal patients with metastatic breast cancer. "
10/01/2000 - "Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol."
06/01/1991 - "The next generation of adjuvant trials in breast cancer needs to explore the potential of an alternating tamoxifen/megestrol regimen."
10/01/1999 - "Results from a phase III trial indicate that exemestane achieves a similar objective response rate to megestrol as a second-line therapy; however, exemestane achieved a significantly longer duration of overall success, time to disease progression and survival time. "
06/01/2000 - "However, the duration of overall success and times to disease progression and treatment failure were significantly prolonged with exemestane compared with megestrol. "
06/01/2000 - "Exemestane is effective in postmenopausal patients with tamoxifen-refractory advanced breast cancer, prolonging time to disease progression and treatment failure and improving survival compared with megestrol treatment. "
01/01/2006 - "In women with hormone-responsive advanced breast cancer, letrozole is superior to tamoxifen in prolonging the time to disease progression and time to treatment failure in a first-line setting, and is at least as effective as anastrozole and more effective than megestrol for some endpoints (in one of two trials) in a second-line setting. "
|3.||Hepatocellular Carcinoma (Hepatoma)
04/06/2001 - "Survival of hepatocellular carcinoma characterized by variant oestrogen receptors was extremely poor (median survival 7 months); megestrol significantly improved survival (18 months) (P = 0.0090). "
11/16/2001 - "Megestrol treatment in patients with hepatocellular carcinoma."
04/06/2001 - "Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors."
02/01/2010 - "Megestrol and embryonic extracts in the treatment of advanced hepatocellular carcinoma: A prospective randomized trial in the pre-sorafenib era."
04/01/2005 - "Nine cirrhotic patients with advanced hepatocellular carcinoma received oral megestrol (160 mg/day) and thalidomide (from 50 mg/day to the maximal tolerated dose). "
12/01/2004 - "Megestrol has also been used as an appetite stimulant for patients with human immunodeficiency virus and malignancy who experience cachexia and wasting; also, megestrol can be beneficial in relieving hot flashes in women and men. "
06/01/2002 - "depot MPA injections provides significant and long-lasting relief from postmenopausal hot flashes in patients with a history of breast cancer, offering an alternative to estrogen replacement therapy or prolonged administration of oral megestrol."
06/01/2002 - "Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study."
04/30/1995 - "The results of the study indicate comparable efficacy (using tumor clearance as an end point) of DES and Megestrol. "
03/01/1989 - "The results of the study indicate comparable efficacy (using tumor clearance as an end-point) of DES and Megestrol. "
02/01/2010 - "At 3 months, tumor burden was more frequently stable with megestrol, while performance status was significantly better in patients treated with Synchro-Levels. "
02/01/2010 - "Most patients had multifocal disease (75% in megestrol and 59% in Synchro-Levels) and there was a significant difference in tumor burden, with more advanced disease in the megestrol arm (P = 0.0002). "
11/01/2005 - "A 21- x 18-mm residual area of neoplasm in the lung completely resolved 3 months after treatment with megestrol. "
|6.||Gonadotropin-Releasing Hormone (GnRH)
|9.||Megestrol Acetate (Borea)
|1.||Combination Drug Therapy (Combination Chemotherapy)
|2.||Estrogen Replacement Therapy